|
|
|
|
|
|
Companies > Clinical
|
|
|
Milo Biotechnology is developing novel therapies based on follistatin, a protein that increases muscle mass and strength. Milo is targeting rare neuromuscular diseases, initiating a Phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis.
Funders:
North Coast Opportunity Fund, JumpStart
|
|
|
|
|